Opinion|Videos|May 29, 2024
Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
Author(s)Neal Shore, MD
A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are the potential advantages of the novel gene therapy nadofaragenefiradenovec compared to standard-of-care therapies for patients with BCG-unresponsive NMIBC? Discuss the clinical significance of the 5-year bladder preservation and overall survival rates reported.
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
COPD Deaths Rival Heart Failure, Exceed Prostate and Breast Cancer
2
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
5